Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 4
2015 3
2017 3
2018 1
2019 2
2020 8
2021 17
2022 18
2023 16
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Vaccines' New Era-RNA Vaccine.
Zhou W, Jiang L, Liao S, Wu F, Yang G, Hou L, Liu L, Pan X, Jia W, Zhang Y. Zhou W, et al. Viruses. 2023 Aug 18;15(8):1760. doi: 10.3390/v15081760. Viruses. 2023. PMID: 37632102 Free PMC article. Review.
Circular RNA vaccine in disease prevention and treatment.
Niu D, Wu Y, Lian J. Niu D, et al. Signal Transduct Target Ther. 2023 Sep 11;8(1):341. doi: 10.1038/s41392-023-01561-x. Signal Transduct Target Ther. 2023. PMID: 37691066 Free PMC article. Review.
Perspectives on RNA Vaccine Candidates for COVID-19.
Borah P, Deb PK, Al-Shar'i NA, Dahabiyeh LA, Venugopala KN, Singh V, Shinu P, Hussain S, Deka S, Chandrasekaran B, Jaradat DMM. Borah P, et al. Front Mol Biosci. 2021 Mar 25;8:635245. doi: 10.3389/fmolb.2021.635245. eCollection 2021. Front Mol Biosci. 2021. PMID: 33869282 Free PMC article. Review.
RNA-based therapeutics for neurological diseases.
Anthony K. Anthony K. RNA Biol. 2022;19(1):176-190. doi: 10.1080/15476286.2021.2021650. Epub 2021 Dec 31. RNA Biol. 2022. PMID: 35067193 Free PMC article. Review.
Self-amplifying RNA vaccines for infectious diseases.
Bloom K, van den Berg F, Arbuthnot P. Bloom K, et al. Gene Ther. 2021 Apr;28(3-4):117-129. doi: 10.1038/s41434-020-00204-y. Epub 2020 Oct 22. Gene Ther. 2021. PMID: 33093657 Free PMC article. Review.
This approach may enable a quicker response to emerging disease outbreaks, as is evident from the swift pursuit of RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical …
This approach may enable a quicker response to emerging disease outbreaks, as is evident from the swift pursuit of RNA vaccine …
Self-Replicating RNA Vaccine Delivery to Dendritic Cells.
Démoulins T, Englezou PC, Milona P, Ruggli N, Tirelli N, Pichon C, Sapet C, Ebensen T, Guzmán CA, McCullough KC. Démoulins T, et al. Methods Mol Biol. 2017;1499:37-75. doi: 10.1007/978-1-4939-6481-9_3. Methods Mol Biol. 2017. PMID: 27987142 Review.
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design.
Pfeifer BA, Beitelshees M, Hill A, Bassett J, Jones CH. Pfeifer BA, et al. NPJ Syst Biol Appl. 2023 Nov 30;9(1):60. doi: 10.1038/s41540-023-00323-3. NPJ Syst Biol Appl. 2023. PMID: 38036580 Free PMC article. Review.
This review will describe how synthetic biology principles can augment RNA-based treatments through optimizing not only the vaccine antigen, therapeutic construct, therapeutic activity, and delivery vector. The enhancement of RNA vaccine technology through implement …
This review will describe how synthetic biology principles can augment RNA-based treatments through optimizing not only the vaccine antigen, …
Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
Larsen SE, Baldwin SL, Coler RN. Larsen SE, et al. Int J Infect Dis. 2023 May;130 Suppl 1:S47-S51. doi: 10.1016/j.ijid.2023.03.035. Epub 2023 Mar 23. Int J Infect Dis. 2023. PMID: 36963657 Free PMC article. Review.
RESULTS: Our preclinical data are the first to report that RNA platforms are a viable system for TB vaccines and should be pursued with high-priority M.tb antigens containing cluster of differentiation (CD4+) and CD8+ T-cell epitopes. CONCLUSION: This RNA vaccine sh …
RESULTS: Our preclinical data are the first to report that RNA platforms are a viable system for TB vaccines and should be pursued with high …
Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y, Zhu X, Tang C, Guan X, Zhang W. Zhu Y, et al. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188593. doi: 10.1016/j.bbcan.2021.188593. Epub 2021 Jul 17. Biochim Biophys Acta Rev Cancer. 2021. PMID: 34280474 Review.
., individualized peptide vaccine, cancer-testis antigen (CTA), new antigen vaccine, RNA vaccine and chimeric antigen receptor modified T cells (CAR-T)). ...
., individualized peptide vaccine, cancer-testis antigen (CTA), new antigen vaccine, RNA vaccine and chimeric antigen receptor …
64 results